Plecanatide
FDA-approved product (tablet, oral), marketed as Trulance.
- Registered studies
- 15
- Lab records
- 0
- Pathogens at ≥40%
- 4 of 4
Chemical structure
Existing / approved use
Documented · FDA, WHO, ChEMBLApproved for
- Constipation
Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗
- WHO therapeutic group
- Other drugs for constipation
- FDA pharmacologic class
- Guanylate Cyclase-C Agonist FDA label ↗
- Anti-infective classification
- Not classified as an anti-infective.
Repurposing investigation
This medicine is being investigated here for AI-predicted antimicrobial activity against K. pneumoniae, MRSA, E. coli and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.
AI-predicted activity
AI prediction · nothing measured- MRSA74.4% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
- E. coli60.1% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
- K. pneumoniae52.2% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
- M. tuberculosis59.5% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.
Evidence
Clinical and experimental
Documented evidenceClinical
15registered studies name this medicine, for any condition. See them below.
Experimental
No evidence found
No laboratory measurement against the four pathogens in the ChEMBL records loaded here.
Docking
Computational · nothing measuredDihydrofolate reductase ↗ (E. coli)
Not yet docked: queued in the docking rundetails
KPC-2 carbapenemase ↗ (K. pneumoniae)
Not yet docked: queued in the docking rundetails
Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)
Not yet docked: queued in the docking rundetails
Dihydrofolate reductase ↗ (MRSA)
Not yet docked: queued in the docking rundetails
AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.
Other medicines to investigate
AI prediction · nothing measuredOther repurposing candidates: approved medicines besides Plecanatide with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.
Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.
- SotorasibExisting use: Neoplasm, Non-small cell lung carcinoma51.3% AI-predicted activityagainst K. pneumoniae50+ registered studies
- Lanreotide AcetateExisting use: Acromegaly, Carcinoid syndrome50.5% AI-predicted activityagainst K. pneumoniae50+ registered studies
- Terlipressin AcetateExisting use: Hepatorenal syndrome, Kidney failure, Renal insufficiency49.5% AI-predicted activityagainst K. pneumoniae7 registered studies
- LetermovirExisting use: Cytomegalovirus infection, Infection, Viral disease49.0% AI-predicted activityagainst K. pneumoniae50+ registered studies
- Codeine SulfateExisting use: Cough, Drug dependence, Migraine disorder and 2 more48.8% AI-predicted activityagainst K. pneumoniae23 registered studies
- Bromocriptine MesylateExisting use: Acromegaly, Adenoma, Hyperprolactinemia and 4 more48.5% AI-predicted activityagainst K. pneumoniae50+ registered studies
- PimecrolimusExisting use: Atopic eczema, Eczematoid dermatitis48.3% AI-predicted activityagainst K. pneumoniae50+ registered studies
- LypressinExisting use: Vasopressin and analogues48.2% AI-predicted activityagainst K. pneumoniae50+ registered studies
- Degarelix AcetateExisting use: Prostate adenocarcinoma, Prostate cancer, Prostate carcinoma48.2% AI-predicted activityagainst K. pneumoniae50+ registered studies
- OlaparibExisting use: Breast cancer, Breast carcinoma, Breast neoplasm and 9 more48.1% AI-predicted activityagainst K. pneumoniae50+ registered studies
- Dolutegravir SodiumExisting use: HIV infection, HIV-1 infection47.9% AI-predicted activityagainst K. pneumoniae50+ registered studies
- Folic AcidExisting use: Acne, Anemia, Anemia (phenotype) and 8 more47.8% AI-predicted activityagainst K. pneumoniae50+ registered studies
Registered studies
A registration describes a study; it does not establish a positive result.
This is a Randomized, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study of the Efficacy and Safety of 2 Weight-based Treatment Groups of Plecanatide Versus Placebo in Children and Adolescent Participants 6 to Less Than 18 Years of Age With FC
NCT07723924 · start 2026-06-01
Registered record
- Registry ID
- NCT07723924
- Conditions
- Functional Constipation (FC)
- Interventions
- plecanatide; Placebo
- Study type
- INTERVENTIONAL
- Phase
- Phase 2
- Registry status
- Active not recruiting
- Start
- 2026-06-01
- Completion
- 2027-10-18
- Enrolment
- 180
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionFunctional Constipation (FC)Interventionplecanatide; PlaceboPhasePhase 2Registry statusActive not recruitingGCC Agonist Signal in the Small Intestine
NCT05107219 · start 2022-11-30
Registered record
- Registry ID
- NCT05107219
- Conditions
- Barrett Esophagus; Gastroesophageal Reflux Disease; Malignant Digestive System Neoplasm
- Interventions
- Biopsy; Biospecimen Collection; Esophagogastroduodenoscopy; Linaclotide; Plecanatide
- Study type
- INTERVENTIONAL
- Phase
- Phase 1
- Registry status
- Completed
- Start
- 2022-11-30
- Completion
- 2026-02-06
- Enrolment
- 43
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionBarrett Esophagus; Gastroesophageal Reflux Disease; Malignant Digestive System NeoplasmInterventionBiopsy; Biospecimen Collection; Esophagogastroduodenoscopy; Linaclotide +1 morePhasePhase 1Registry statusCompletedEfficacy and Safety of Plecanatide Comparing With Placebo in the Treatment of Functional Constipation
NCT05151328 · start 2022-03-18
Registered record
- Registry ID
- NCT05151328
- Conditions
- Functional Constipation
- Interventions
- Plecanatide
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Completed
- Start
- 2022-03-18
- Completion
- 2023-10-26
- Enrolment
- 648
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionFunctional ConstipationInterventionPlecanatidePhasePhase 3Registry statusCompletedEfficacy and Safety of Plecanatide in Children 6 to <18 Years With Irritable Bowel Syndrome With Constipation (IBS-C)
NCT03596905 · start 2018-06-30
Registered record
- Registry ID
- NCT03596905
- Conditions
- Irritable Bowel Syndrome With Constipation
- Interventions
- Plecanatide; Matching placebo
- Study type
- INTERVENTIONAL
- Phase
- Phase 2
- Registry status
- Completed
- Start
- 2018-06-30
- Completion
- 2024-11-25
- Enrolment
- 218
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionIrritable Bowel Syndrome With ConstipationInterventionPlecanatide; Matching placeboPhasePhase 2Registry statusCompletedA Postmarketing Study of Plecanatide in Breast Milk of Lactating Women Treated With TRULANCE®
NCT03551873 · start 2018-06-21
Registered record
- Registry ID
- NCT03551873
- Conditions
- Chronic Idiopathic Constipation
- Interventions
- Plecanatide
- Study type
- OBSERVATIONAL
- Phase
- Not recorded
- Registry status
- Completed
- Start
- 2018-06-21
- Completion
- 2018-12-14
- Enrolment
- 7
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionChronic Idiopathic ConstipationInterventionPlecanatidePhaseNot recordedRegistry statusCompletedAn Efficacy and Safety Study of Plecanatide in Adolescents 12 to <18 Years of Age With Chronic Idiopathic Constipation
NCT03120520 · start 2017-01
Registered record
- Registry ID
- NCT03120520
- Conditions
- Chronic Idiopathic Constipation
- Interventions
- Plecanatide; Matching placebo
- Study type
- INTERVENTIONAL
- Phase
- Phase 2
- Registry status
- Completed
- Start
- 2017-01
- Completion
- 2018-09-07
- Enrolment
- 124
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionChronic Idiopathic ConstipationInterventionPlecanatide; Matching placeboPhasePhase 2Registry statusCompletedLong Term Safety Study of Plecanatide
NCT02706483 · start 2016-01
Registered record
- Registry ID
- NCT02706483
- Conditions
- Irritable Bowel Syndrome
- Interventions
- Plecanatide
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Completed
- Start
- 2016-01
- Completion
- 2017-06
- Enrolment
- 2,272
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionIrritable Bowel SyndromeInterventionPlecanatidePhasePhase 3Registry statusCompletedSecond Plecanatide Study In Irritable Bowel Syndrome With Constipation (IBS-C)
NCT02493452 · start 2015-06
Registered record
- Registry ID
- NCT02493452
- Conditions
- Irritable Bowel Syndrome Characterized by Constipation
- Interventions
- Plecanatide; Placebo
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Completed
- Start
- 2015-06
- Completion
- 2017-02
- Enrolment
- 1,135
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionIrritable Bowel Syndrome Characterized by ConstipationInterventionPlecanatide; PlaceboPhasePhase 3Registry statusCompletedThe Plecanatide Irritable Bowel Syndrome With Constipation Study (IBS-C)
NCT02387359 · start 2014-12
Registered record
- Registry ID
- NCT02387359
- Conditions
- Irritable Bowel Syndrome Characterized by Constipation
- Interventions
- Plecanatide; Placebo
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Completed
- Start
- 2014-12
- Completion
- 2017-02
- Enrolment
- 1,054
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionIrritable Bowel Syndrome Characterized by ConstipationInterventionPlecanatide; PlaceboPhasePhase 3Registry statusCompleted12-Week Study of Plecanatide for CIC (The National CIC3 Study)
NCT02122471 · start 2014-04
Registered record
- Registry ID
- NCT02122471
- Conditions
- Chronic Idiopathic Constipation
- Interventions
- Plecanatide; Placebo
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Completed
- Start
- 2014-04
- Completion
- 2015-07
- Enrolment
- 1,410
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionChronic Idiopathic ConstipationInterventionPlecanatide; PlaceboPhasePhase 3Registry statusCompleted12-Week Study of Plecanatide for CIC (The CIC3 Study)
NCT01982240 · start 2013-11
Registered record
- Registry ID
- NCT01982240
- Conditions
- Chronic Idiopathic Constipation
- Interventions
- Plecanatide; Placebo; Bisacodyl
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Completed
- Start
- 2013-11
- Completion
- 2015-06
- Enrolment
- 1,394
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionChronic Idiopathic ConstipationInterventionPlecanatide; Placebo; BisacodylPhasePhase 3Registry statusCompletedOpen-label Extension (OLE) Study of Plecanatide for Chronic Idiopathic Constipation (CIC)
NCT01919697 · start 2013-08
Registered record
- Registry ID
- NCT01919697
- Conditions
- Chronic Idiopathic Constipation
- Interventions
- Plecanatide
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Completed
- Start
- 2013-08
- Completion
- 2016-03
- Enrolment
- 2,370
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionChronic Idiopathic ConstipationInterventionPlecanatidePhasePhase 3Registry statusCompletedThe Plecanatide Irritable Bowel Syndrome With Constipation Study (IBS-C)
NCT01722318 · start 2012-11
Registered record
- Registry ID
- NCT01722318
- Conditions
- Irritable Bowel Syndrome Characterized by Constipation
- Interventions
- Plecanatide; Placebo
- Study type
- INTERVENTIONAL
- Phase
- Phase 2
- Registry status
- Completed
- Start
- 2012-11
- Completion
- 2014-10
- Enrolment
- 428
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionIrritable Bowel Syndrome Characterized by ConstipationInterventionPlecanatide; PlaceboPhasePhase 2Registry statusCompletedThe Plecanatide Chronic Idiopathic Constipation (CIC) Study
NCT01429987 · start 2011-10
Registered record
- Registry ID
- NCT01429987
- Conditions
- Chronic Idiopathic Constipation
- Interventions
- plecanatide; Placebo
- Study type
- INTERVENTIONAL
- Phase
- Phase 2 / Phase 3
- Registry status
- Completed
- Start
- 2011-10
- Completion
- 2012-12
- Enrolment
- 951
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionChronic Idiopathic ConstipationInterventionplecanatide; PlaceboPhasePhase 2 / Phase 3Registry statusCompletedSP-304 Dose Ranging Study in Patients With Chronic Idiopathic Constipation
NCT01053962 · start 2010-03
Registered record
- Registry ID
- NCT01053962
- Conditions
- Chronic Idiopathic Constipation
- Interventions
- SP-304 0.3 mg; SP-304 1.0 mg; SP-304 3.0 mg; SP-304 9.0 mg; Placebo
- Study type
- INTERVENTIONAL
- Phase
- Phase 2
- Registry status
- Completed
- Start
- 2010-03
- Completion
- 2010-08
- Enrolment
- 84
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionChronic Idiopathic ConstipationInterventionSP-304 0.3 mg; SP-304 1.0 mg; SP-304 3.0 mg; SP-304 9.0 mg +1 morePhasePhase 2Registry statusCompleted